Compounds > dofequidar
Page last updated: 2024-09-05

dofequidar and paclitaxel

dofequidar has been researched along with paclitaxel in 2 studies

Compound Research Comparison

Studies
(dofequidar)		Trials
(dofequidar)		Recent Studies (post-2010)
(dofequidar)		Studies
(paclitaxel)		Trials
(paclitaxel)		Recent Studies (post-2010) (paclitaxel)
402531,8745,72915,395

Protein Interaction Comparison

ProteinTaxonomydofequidar (IC50)paclitaxel (IC50)
Integrin beta-3Homo sapiens (human)0.034
Integrin alpha-V Homo sapiens (human)0.034
ATP-dependent translocase ABCB1Homo sapiens (human)2.598
Botulinum neurotoxin type A Clostridium botulinum5.2
UDP-glucuronosyltransferase 2B7Homo sapiens (human)4.9
UDP-glucuronosyltransferase 1-6Homo sapiens (human)4.9
Substance-K receptorHomo sapiens (human)6.125
UDP-glucuronosyltransferase 1A1 Homo sapiens (human)4.9
UDP-glucuronosyltransferase 1A4Homo sapiens (human)4.9
UDP-glucuronosyltransferase 2B10 Homo sapiens (human)4.9
Delta-type opioid receptorHomo sapiens (human)4.202
Tyrosine-protein kinase MerHomo sapiens (human)4.9
Tubulin beta-3 chainHomo sapiens (human)0.0082
Beta-tubulin Leishmania donovani1
Nucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)7.9433
Solute carrier organic anion transporter family member 1B3Homo sapiens (human)0.26
Solute carrier organic anion transporter family member 1B1Homo sapiens (human)0.28

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hirata, H; Matsuba, Y; Naito, M; Sato, S; Tsuruo, T1
Aoki, J; Kimura, Y; Kohno, M; Nakanishi, O; Ooka, H; Tsuruo, T1

Other Studies

2 other study(ies) available for dofequidar and paclitaxel

ArticleYear
MS-209, a quinoline-type reversal agent, potentiates antitumor efficacy of docetaxel in multidrug-resistant solid tumor xenograft models.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:2

    Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Cycle; Cell Division; Cell Line; Docetaxel; Drug Resistance, Neoplasm; Female; Flow Cytometry; Humans; Inhibitory Concentration 50; Maximum Tolerated Dose; Mice; Mice, Inbred BALB C; Mitosis; Models, Chemical; Neoplasm Transplantation; Paclitaxel; Quinolines; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Time Factors; Tumor Cells, Cultured

2002
P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel.
    Cancer chemotherapy and pharmacology, 2002, Volume: 49, Issue:4

    Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Caco-2 Cells; Cyclosporine; Cyclosporins; Humans; Male; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Paclitaxel; Quinolines; Rats; Rats, Sprague-Dawley

2002